At a time when drugmakers Eli Lilly & Co. and Novo Nordisk are scrambling to meet demand for their popular weight-loss medications, other manufacturers are struggling. Bristol-Myers Squibb has announced that it plans to cut $1.5 billion in expenses by the end of 2025, including laying off more than 2,200 employees.
Patents are set to expire for the company's two top-selling drugs – the blood thinner Eliquis, which it sells with Pfizer, and the cancer immunotherapy Opdivo. Eliquis also is one of the first 10 drugs the government has targeted for price negotiations under the Inflation Reduction Act. Its third highest-grossing product, the multiple myeloma treatment Revlimid, already faces limited generic competition.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Critical BenefitsPRO information including cutting edge post-reform success strategies, access to educational webcasts and videos, resources from industry leaders, and informative Newsletters.
- Exclusive discounts on ALM, BenefitsPRO magazine and BenefitsPRO.com events
- Access to other award-winning ALM websites including ThinkAdvisor.com and Law.com
Already have an account? Sign In
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
